Objective: Methylation of cytosine in CG dinucleotides within regulatory elements is believed to silence gene expression. These Ž . dinucleotides occur in certain important regulatory elements in the promoter region of the human b-myosin heavy chain b-MHC gene. Ž We therefore investigated whether methylation of these elements correlates with b-MHC gene transcription in human 'expressing' right . Ž . Ž . atrial and 'non-expressing' peripheral blood leucocytes cells. Methods: We employed 2 techniques to assess promoter methylation: i analysis of the susceptibility to digestion of a particular CCGG restriction site in the promoter region when genomic DNA is cleaved with Ž . Ž . Ž . the restriction endonucleases MspI methylation-insensitive and HpaII methylation-sensitive , and ii the bisulphite-PCR method to examine in detail the methylation patterns of 3 important regulatory elements that contain CG dinucleotides. b-MHC mRNA expression in right atrium and leucocytes was assessed using reverse-transcription-PCR with specific primers that do not detect a-MHC cDNA. Results: The digestion pattern observed with MspI or HpaII indicated that the CCGG site was almost completely methylated in leucocytes, but relatively unmethylated in atrial myocardium from the same patients. When methylation was examined with the bisulphite-PCR method we found a reciprocal relationship between the level of b-MHC mRNA expression in leucocytes and atrial myocardium and the degree of methylation of CG dinucleotides in the 5 X regulatory elements of the gene. Conclusions: Tissue-specific methylation of the human b-MHC gene promoter may play a role in determining the pattern of expression of this gene. Furthermore, alteration of the level of methylation may underlie the changes in transcription of this gene that occur, for example, when atrial or ventricular myocardium hypertrophies. q
Introduction
Myosin molecules in the thick filament of the sarcomere are encoded by 2 closely related genes, the a-and Ž . b-myosin heavy chain genes a-MHC and b-MHC which are expressed in a tissue specific manner. In man, slow twitch skeletal muscle is the only tissue, apart from the heart, that expresses b-MHC. In the normal adult human ventricle b-MHC predominates, whilst in atrial tissue a-MHC is more prevalent, although there is still substantial w x expression of b-MHC 1 . In rodents, normal left ventricular myocardium expresses mainly a-MHC. In both ventricles and atria, the MHC genes are differentially expressed ) Ž .
Ž . Corresponding author. Tel.: q44 181 383 3219; Fax: q44 181 383 2066; E-mail: d.nunez@rpms.ac.uk in response to stimuli such as pressure overload and thyroid hormone.
The transcriptional control mechanisms responsible for these differences in b-MHC expression are not well underw x stood 2-4 , although several regulatory sequences at the 5 X -end of the gene have been identified, including a thyroid response element which represses the b-MHC gene, but activates the a-MHC gene, and strong positive and negative elements between positions y340 and y200 upw x stream from the transcription start site 3 . Some of these Ž . regulatory elements contain CG dinucleotides Table 1 that are susceptible to methylation at the 5 X position of the cytosine base, a process which can silence the expression ( ) Table 1 w x Adapted from 3 . w x of a gene 5, 6 . We therefore reasoned that differential methylation of one or more CG-containing regulatory elements in the b-MHC gene may affect its transcription and could underlie the differences in expression of this gene between tissues.
Methods

Preparation of DNA from human peripheral blood leucocytes and cardiac muscle
Right atrial tissue and a 10 ml peripheral venous blood sample were obtained at the time of cardiac surgery from 3 patients undergoing coronary artery bypass surgery. Genomic DNA was then extracted using the Nucleon II Ž . genomic DNA extraction kit Scotlab according to the manufacturer's protocol. At the end of the protocol the DNA was precipitated with ethanol and pelleted by centrifugation, before being resuspended in 1 ml nuclease-free sterile water.
Genomic DNA was extracted from 1 g blocks of human right atrial tissue using a similar protocol designed for Ž solid tissues as recommended by the supplier Nucleon II . kit, Scotlab .
Preparation of RNA from human peripheral blood leucocytes and cardiac muscle
Human peripheral blood leucocytes were concentrated w x using a dextran density gradient 7 . The white blood cells were pelleted by centrifugation at 1200 rpm for 6 min.
The white cell pellet and right atrial tissue were stored at y808C until RNA extraction was performed using the Hybaid Ribolyser kit according to the manufacturer's pro-Ž . tocol Life Sciences . At the end of the procedure, the RNA was precipitated with isopropanol. The RNA pellet was then washed with saltrethanol solution, air-dried, and resuspended in 100 ml nuclease-free water.
(
ReÕerse transcription-polymerase chain reaction RT-) PCR
The reverse transcription reaction was performed as w x previously described 8 , using 150 pmol of 12 mer randomer, 4 ml RNA and 9 U MMLV reverse transcriptase Ž . Pharmacia . The reaction was incubated at 378C for 2 h, and then made up to 100 ml with nuclease-free distilled water.
For amplification of b-MHC cDNA, 2 primers were designed from the human b-MHC gene sequence targeted w x Ž to the adjacent ends of exons 5-6 and 11-12 9 forward primer: 5 X -CAGTACATGCTGACAGACAGA; reverse X . primer: 5 -GCACATCAAAAGCGTTATCAG . The PCR reaction mixture contained 1.5 mmolrl MgCl , 200 2 mmolrl deoxynucleotides, 1 unit of Prozyme DNA poly-Ž . merase Bioline , 2.5 ml of cDNA and 1 mm each primer. Ž PCR amplification was performed for 35 cycles denaturation: 938C 30 s; annealing 588C 30 s; extension 728C 1 . min; final extension 728C 10 min . The PCR products were resolved by electrophoresis through a 1.8% agarose gel and visualised using ethidium bromide staining. In addition to flanking intronic sequences, there were 3 mismatches of the primers at the 3 X end when compared with the a-MHC cDNA sequence, which, as a consequence should not be amplified. After electrophoretic separation, representative samples of the amplified atrial DNA bands were purified Ž from the agarose gel using GeneClean glass milk Bio . 101 . The source of the PCR products was determined by dideoxy sequencing with the Amplitaq FS Cycle Sequenc-Ž . ing kit as recommended by the supplier Perkin Elmer . Cleavage with HpaII will only occur if the cytosine within the CG dinucleotide is unmethylated, whilst MspI cleavage is not dependent on the methylation status. Therefore, using this pair of restriction enzymes it is possible to determine whether the cytosine base is methylated or not. Ž . Genomic DNA 2 mg was pre-incubated with 1 ml of Ž . Ž . MspI 20 U or HpaII 10 U and 1 ml of 10= restriction Ž . enzyme buffer New England Biolabs at 378C for 2 h. The partially-digested DNA was denatured at 958C for 5 min ( )before adding a further 1 ml of restriction enzyme and leaving the reagents to incubate overnight at 378C. The restriction enzyme was then inactivated by incubating the reaction mix at 958C for 30 min. In the positive 'no-enzyme' control the restriction enzymes were omitted, and 2 ml of the buffer were used instead. 2.5 ml of the digested or 'buffer-only' DNA were then added to a standard PCR mixture containing 0.75 mmolrl MgCl and the specific 2 primers flanking the CCGG site in the promoter region of the gene. PCR amplification was performed for 35 cycles Ždenaturation: 938C 30 s; annealing 588C 30 s; extension . 728C 1 min; final extension 728C 10 min . The PCR products were resolved by electrophoresis through a 1.8% agarose gel and visualised using ethidium bromide staining.
Analysis of methylation patterns using isoschizomeric restriction enzymes and PCR
Under the conditions described above, no amplification band should be seen after digesting the genomic DNA with MspI; this acts as a negative control. However, the extreme sensitivity of the PCR means that on occasions low residual levels of undigested DNA are detectable. If the site is completely unmethylated, the DNA should be cleaved by HpaII, and no band will be seen after PCR amplification. The target sequence will be amplified nor-Ž . mally i if the site is completely methylated or hemi-meth-Ž . ylated and no digestion occurs with HpaII, and ii when the genomic DNA is incubated with restriction enzyme buffer only.
Analysis of methylation patterns using the bisulphite-PCR method
This method relies on the ability of bisulphite to convert efficiently a cytosine residue to uracil in single-stranded DNA, whilst leaving 5-methylcytosine residues unaltered w x 10,11 . The conversion of cytosine to uracil produces 2 Ž non-complementary modified DNA strands uracils cannot . pair with guanines on the opposite strand which can then be amplified separately by PCR with primer pairs specific Ž for each converted strand during PCR a uracil base is read as thymine by the DNA polymerase, while 5-methylcyto-. sine, which remains unchanged, is read as cytosine . . Twenty-four ml of genomic DNA 250 mgrml was digested for 1 h at 378C with 3 ml of the restriction enzyme BamHI and 3 ml of 10= restriction enzyme buffer in a final volume of 30 ml. 6 ml of 1.8 M NaOH Ž was added final concentration 0.3 M in a final volume of . 36 ml and incubated at 378C for 15 min to denature the Ž DNA. 4 ml 10 mmolrl hydroquinone final concentration . Ž 0.5 mmolrl and 40 ml 4 M sodium bisulphite pH 5 final . Ž . concentration 2 M were added final volume of 80 ml . Ž All solutions were freshly prepared with minimal shaking . of the sodium bisulphite solution . The sample was then covered with oil and incubated for 6 cycles of temperature cycling at 558C for 3 h and 958C for 3 min. Our unpublished preliminary results showed that this protocol ensured complete conversion of cytosine bases to uracil by bisulphite, whilst methylcytosines remained unchanged. The DNA was purified using the Wizard DNA Clean-Up Ž . system according to manufacturer's instructions Promega , Ž . and eluted in 50 ml of Tris HCl 50 mmolrl, pH 8.0 Ž . rEDTA 1 mmolrl buffer. 10 ml of 1.8 M NaOH were added, and the reagents were incubated at 378C for 15 min to ensure complete desulphonation. The solution was neutralised by adding 40 ml 7.5 M ammonium acetate pH 7, and the DNA was then precipitated with 100 ml of isopropanol. After the DNA was pelleted by centrifuging at 14 000 g for 15 min, the supernatant was removed and the pellet was resuspended in 10 ml of distilled water. This bisulphite-converted DNA was amplified for 40 cycles by Ž PCR denaturation: 938C 30 s; annealing 558C 30 s; exten-. sion 728C 1 min; final extension 728C 10 min using a standard reaction mix containing 1 U Prozyme and 2 mmolrl MgCl . Primers were designed to recognise only TATATATATAAAACAAC . Finally, the amplified DNA was sequenced using the AmpliTaq FS automated cycle-Ž . sequencing kit Perkin-Elmer as recommended by the supplier. The fluorescent dideoxy terminated products were resolved on an ABI 373 automated sequencer.
Declaration
The investigation conforms with the principles outlined Ž in the Declaration of Helsinki Cardiovascular Research . 1997;35:2-3 .
Results
Methylation patterns in lymphocytes and myocytes
Amplification of genomic DNA after digestion with the restriction enzymes MspI and HpaII permits assessment of the degree of methylation of specific CCGG restriction sites. Fig. 1 shows the results of amplifying a ; 450 bp Ž . segment spanning a CCGG site bases 2462 to 2465 in the promoter region of the b-MHC gene using myocardial and leucocyte DNA. In DNA samples pre-digested with MspI, an enzyme which cleaves the CCGG site irrespective of the level of methylation of the CG dinucleotide, very little, or no, DNA amplification is observed. Where weak bands Ž . are observed e.g. patients 2 and 3 , this is likely to represent amplification of very small amounts of undigested DNA. On the other hand, a bright amplification band is observed in the HpaII-digested samples from leucocytes, but not atrial myocardium, indicating that the CG dinucleotide is methylated in leucocyte, but not myocardial genomic DNA. An amplification band is observed in all the samples pre-treated with restriction enzyme buffer alone; this acts as a positive control. Ž Bisulphite converts unmethylated cytosine to uracil de-. tected as thymine after PCR , whereas methylated cytosine Fig. 2 . Bisulphite-PCR analysis of methylation of the promoter region of the b-MHC gene. Unmethylated cytosines occurring outside CG dinu-Ž cleotides are converted by bisulphite to uracil which is detected as . thymine after PCR , whereas methylcytosines remain unchanged. Typical electropherograms from the ABI 373 automated sequencer are shown in the region of the CG dinucleotides in the 3 regulatory elements of the b-MHC gene that contain these dinucleotides. In the leucocyte samples, the CG dinucleotides remain largely unchanged after bisulphite treatment. However, in the atrial samples from the same patient there is greater C ™T conversion in CG dinucleotides, indicating that the degree of methylation of CG dinucleotides is relatively low. remains unchanged. At the CCGG site in the b-MHC promoter, the results were consistent with those obtained by restriction analysis with HpaII and MspI and indicated that there was almost complete demethylation of the CG dinucleotide in atrial tissue, the reverse being the case in Ž . leucocytes data not shown . Fig. 2 shows the electropherograms of samples from the same individual in the region of the CG dinucleotides in the 3 regulatory elements of the b-MHC gene that contain these dinucleotides Ž . Table 1 . In the leucocyte samples, the CG dinucleotides Ž remain largely unchanged after bisulphite treatment i.e. C . peak )) T peak . On the other hand, in the atrial samples we have found that there is variable C ™ T conversion in the regulatory elements, but with a significant T peak present in all cases, indicating that many of the CG dinucleotides are unmethylated. When the degree of methylation was compared between individuals, we observed consistent methylation in leucocyte DNA in the 3 elements similar to that shown in Fig. 2 . However, in atrial DNA samples the level of methylation in each of the elements Ž varied between individuals Fig. 3 shows the results for . one of the elements in 3 different individuals .
Expression of the b-MHC gene in leucocytes and atrial myocytes
To assay the steady-state prevalence of b-MHC mRNA we used RT-PCR to amplify b-MHC cDNA. After sequencing PCR products from atrial samples with fluorescent dideoxy terminators, we compared the sequence of the amplification bands in the region of exon 11 of b-MHC and a-MHC, where there are significant differences in nucleotide sequence. We established conclusively that the single ; 550 bp product obtained after PCR of atrial samples was derived solely from the b-MHC cDNA, Ž without contamination with a-MHC cDNA data not . shown .
As shown in Fig. 4 , b-MHC cDNA was readily detectable after a single round of amplification in all atrial myocardial samples, but not in leucocyte cDNA samples, indicating that the steady-state prevalence of b-MHC transcripts in the latter was below the level of detection by this PCR method. The faint bands observed in the leucocyte lanes are non-specific amplification products that commonly arise in the absence of specific products.
Discussion
Here we present evidence which indicates that methylation of regulatory elements within the 5 X region of the b-MHC gene is inversely related to mRNA steady-state levels. Functional assays of b-MHC promoterrreporter plasmids containing progressive deletions of the 5 X region of the gene have revealed that there are strong positive and negative elements between positions y340 and y200 w x upstream from the transcription start site 3 ; some of these contain CG dinucleotides that are susceptible to methylation. We provide evidence that in atrial myocytes these sites are predominantly hypo-methylated and the gene is strongly expressed. In leucocytes, where 'illegitimate' gene transcription has only been observed by nested reverse w x transcription-PCR 12 , and the protein is undetectable, the promoter elements are heavily methylated. Methylation is known to silence genes, and it is likely that these differences in expression are due to reduced transcription, rather Fig. 4 . To validate the reverse transcription-PCR data, we sequenced the ; 550 bp amplification band obtained from the atrial samples. Although the sequences of a-MHC and b-MHC mRNAs are remarkably similar, there are significant base changes in the region of exon 11. These differences were sufficient to confirm that a-MHC cDNA was not detectable in the specific PCR bands observed in the atrial samples shown in Fig. 4 , and demonstrate that the PCR primers used were specific for b-MHC cDNA under our amplification conditions.
After bisulphite conversion, we have observed some variability in the relative C and T peak heights of the electropherograms from different individuals at CG dinucleotides within the regulatory elements in atrial DNA Ž . samples e.g. Fig. 3 . There are 3 possible explanations for these observations. First, it may simply reflect technical artefact due to variability in the efficacy of bisulphite to convert unmethylated cytosines. We do not favour this possibility because we have found that all cytosines that do not occur in CG dinucleotides are consistently converted by this reagent in our protocol. Secondly, the difference may result from complete methylation of a site in some cells and complete demethylation in other myocytes, with the proportions of each type varying between individuals. This may be the case, at least to some extent, given that in atrial tissue there is marked cellular heterogeneity in the expression of each MHC; cells containing only a-MHC Ž presumably with heavy methylation of the b-MHC gene . and complete repression of expression can be found adja-Ž cent to cells expressing only b-MHC containing hypo-. methylated b-MHC promoters , whilst others contain both w x MHCs 13,14 . Finally, it may be due to variable methylation of one or other allele within a single cell. All the myocardial samples analysed in these studies consisted of many thousands of myocytes, and it is not possible to distinguish between the latter two alternatives. We are in the process of refining techniques to assess differential expression of b-MHC alleles using single-cell PCR. However, at present it is not possible to quantify accurately the level of methylation in single-cell preparations.
There are several lines of evidence implicating methylation of critical regulatory regions in the control of expression of a number of genes. For instance, there is an inverse relationship between expression of the murine MyoD gene w x 15 and the avian myosin light chain MLC1f and MLC3f w x genes 16 , and the level of methylation of promoter elements. Similar results have been obtained for a variety w x of non-myocyte genes 17-20 . Alteration of the methylation status of regulatory elements of various genes by in w x vitro methylation analysis 17-25 and by administration of the demethylating agents 5-aza-2 X -deoxycytidine, 5-w x azacytidine or 3-deazaadenosine 5,26-29 has been shown to have a profound effect on their expression. In addition, methylation of cytosine residues is thought to play a major role in producing hemizygous expression of imprinted and X-linked genes by permanently altering chromatin structure or by promoting attachment of methylcytosine binding w x proteins 30-32 .
Our results therefore raise a number of interesting questions. First, the inverse relationship between the level of expression of the b-MHC gene and the degree of methylation of regulatory elements suggests that the latter may be involved in the dramatic changes in cardiac myosin isoforms observed during ontogeny, eventually leading to the establishment of the tissue specific pattern of expression of this gene in the adult. In rats and rabbits, b-MHC is more abundant than a-MHC in the late foetal ventricle. However, soon after birth the isomyosin profile begins to change to the a-MHC form. The rat ventricle then maintains the predominance of a-MHC, whilst the rabbit reverts back towards the b-MHC form. On the other hand, in the human ventricle b-MHC predominates at all stages of development, a-MHC constituting no more than 15% of w x the total myosin in the adult healthy left ventricle 33 . In human atria, a-MHC predominates, but b-MHC is present in substantial amounts and can be up-regulated further by Ž . pressure overload see below .
Secondly, we speculate that during the process of cardiac myocyte hypertrophy changes in genomic DNA methylation may play a role in co-ordinating the programme of w x gene expression 1,4 . Although a myosin isoform shift is not observed in the adult human ventricle in response to hypertrophic stimuli, atrial b-MHC expression increases further in proportion to the extent of atrial distension w x associated with valvular disease 14,34 . When the rodent ventricles hypertrophy there is a 'recapitulation' of the foetal pattern of MHC gene expression which results in up-regulation of b-MHC gene and down-regulation of a-MHC expression, with replacement of a-MHC by bw x MHC in the thick filaments 1 . We propose that in cardiac tissues these changes are accompanied by reciprocal alteration of promoter methylation, whilst in tissues that do not express b-MHC, such as peripheral blood leucocytes, the almost complete methylation of regulatory elements remains relatively fixed.
Finally, we raise the exciting possibility that 'new' cardiac myocytes could be generated by altering the phenotype of non-myocyte ventricular cells such as fibroblasts with agents which demethylate genomic DNA. There are already striking precedents for this. When undifferentiated mouse fibroblasts were treated for 24 h with 5-azacytidine, a cytosine analogue that inhibits DNA methyl-transferases and produces genomic demethylation, a small proportion of the cells differentiated into multinucleate striated musw x X cle cells that twitched 35 . A similar chemical, 5-aza-2 -deoxycytidine, has also been shown to enhance the efficacy of the myogenic determination factor, MyoD, to w x induce expression of myosin in fibroblasts 36,37 . We are now evaluating the efficacy of demethylating agents to change their phenotype of human cardiac fibroblasts into In conclusion, we have demonstrated an inverse relationship between the level of expression of the b-MHC gene and the degree of methylation of 5 X regulatory elements. We propose that methylation of promoter motifs plays a role in the processes determining tissue-specific expression, and perhaps also in the coordinated programme of gene expression that characterises cardiac myocyte hypertrophy.
